STOCKS TELEGRAPH

Tag: biomedical

  • Sintx Technologies, Inc. (SINT) Stock Undergoes Volatility Following News of First FleX SN-PEEK Shipment

    Sintx Technologies, Inc. (SINT) stock prices were up 11.04% as of the market closing on July 27th, 2021, bringing the price per share up to USD$1.71 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 5.85%, bringing it down to USD$1.61.

    FleX SN-PEEK Shipments

    July 27th, 2021 saw SINT stock announce the first shipment of FleX SN-PEEK, its new product that is designed to be used in orthopedic implants. The company’s proprietary product commenced being shipped on July 20th, 2021, combining the singular bioactivity of silicon nitride with the properties of Zeniva PEEK, which was supplied by Solvay.

    About FleX SN-PEEK

    The composite material has been deemed to have a myriad of applications, ranging from spine surgery to joint replacements to craniomaxillofacial medical devices. On the basis of data collected by SINT stock on silicon nitride, FleX SN-PEEK is expected to facilitate faster bone healing, improved radiographic imaging, avoid metal ion release in the body, and have broad-spectrum resistance to infection as compared to PEEK in isolation.

    Advantages of FleX SN-PEEK

    The commencement of the shipping of SINT stock’s FleX SN-PEEK is a major milestone for the company. It continues to allocate resources to leverage the osteogenic and antipathogenic properties of silicon nitride for biomedical applications. The company is confident that the product differentiates itself as being superior with many unmatched benefits. Zaniva PEEK is a biomaterial that has been determined to have many advantages, signaled by its worldwide use. The advantages include favorable material modules, ease of manufacturing, established clinical record, as well as a track record of use in orthopedics.

    SINT Stock Healthcare Scope

    The combination of PEEK with silicon nitride’s osteogenic and antipathogenic properties gives rise to a superior product, FleX SN-PEEK. The catalogue of FleX SN-PEEK products provides access to new biomedical areas like craniomaxillofacial, and foot osteotomy and fusion. The proprietary technology serves to address a large unmet need stemming from surgeons constantly on the lookout for materials and procedures that result in improved outcomes with mitigated complications.

    Future Outlook for SINT

    Armed with the success of the first delivery of its proprietary technology, SINT stock is poised to capitalize on the continued development of FleX SN-PEEK. The company is keen to expand and consolidate its market footprint in order to continue its trajectory of success. Investors are hopeful that management will be able to allocate resources so as to ensure maximum gains in shareholder value.

  • Universe Pharmaceuticals Inc. (UPC) Stock Surges Following Progress on Partnership with Kitanihon

    Universe Pharmaceuticals Inc. (UPC) Stock Surges Following Progress on Partnership with Kitanihon

    Universe Pharmaceuticals Inc. (UPC) stock prices were down by 3.93% as of the market closing on June 29th, 2021, bringing the price down to USD$2.93 at the end of the trading day. Subsequent after-market fluctuations have seen the stock surge by 17.23%, bringing it up to USD$3.47.

    Collaboration with Kitanihon

    May 25th, 2021 saw the company announce having entered into a letter of intent for strategic cooperation with Kitanihon Pharmaceutical. UPC plans to strategically collaborate with a Japanese company that specializes in the research, development, manufacturing, and distribution of healthcare products.

    Details of the LOI

    As per the LOI, the partnership will seek to establish a flagship store on global.jd.com, which is a popular e-commerce platform in China that offers imported products. UPC will operate the flagship store and sell Kitanihon’s products as an exclusive distributor. Distribution of KP’s products will span Chinese and Southeast Asian markets through respective international e-commerce channels, with the aim of fostering growth opportunities for both companies.

    Strategic Partnership

    Furthermore, UPC and KP have agreed to collaborate on the establishing of a medical product research and development center, which will be named Universe Hanhe Medical Research Institute Co., Ltd. Scaffolding by favorable policy treatment from the Chinese government, UPC will make use of its R&D capacity and medicinal resources, while KP will utilize its quality control standards and advanced technologies. Together the two will pool resources towards the development of expanding their portfolio of medical products.

    Joint Venture Facility

    According to the LOI, the achievement of specific strategic goals will lead to the collaborative construction of a manufacturing facility in accordance with the market access requirements from Japan’s Pharmaceutical and Medical Devices Agency (PMDA). The companies will collaborate to ensure the facility will be recognized as a qualified foreign manufacturer of pharmaceutical products, as well as facilitate PMDA certification as a Chinese medicine brand.

    About UPC

    UPC is a pharmaceutical producer and distributor in China that specializes in traditional Chinese medicine derivative products. Its target consumer audience is the elderly, with the aim of addressing physical conditions through the aging process and to facilitate the promotion of their general well-being. With the company’s products being sold in 30 provinces in China, it also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies.

    Future Outlook for UPC

    Armed with the expanded pool of resources from its ongoing partnership, UPC is poised to capitalize on the opportunities afforded to it and continue its trajectory of success. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.